The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Levodopa‐induced dyskinesias
Abstract
Levodopa‐induced dyskinesias (LID) are common and difficult to treat. This review focuses on three issues related to LID: clinical features, classification and rating, pathophysiology and pathogenesis, and management. The three primary clinical syndromes are OFF‐period dystonia, peak‐dose dyskinesia, and diphasic dyskinesia. Several other forms also occur, making the evaluation and choice of treatment complicated. A core component of the pathophysiology of LID is overactivity of the direct striatal output pathway. This pathway provides a direct GABAergic connection by which the striatum inhibits the output regions of the basal ganglia, i.e., the internal globus pallidus and the substantia nigra pars reticulata. Altering dopaminergic dosing and timing can abate dyskinesias, but usually impact the control of parkinsonism. Putative therapies to reduce the problem of dyskinesias could focus on the glutamatergic, GABAergic, α 2 adrenergic, serotonergic (5HT 1A, 5HT 2A), opioid, histamine H 3, adenosine A 2A receptors, the monoamine transport or cannabinoid CB1 receptors systems. The only currently available drug with an evidence‐based recommendation on efficacy for dyskinesia is amantadine. Therapy goals include the prevention of dyskinesia and treatment of dyskinesias that are troublesome clinically. New rating measures to assess severity and disability related to dyskinesia are in the process of development and clinimetric testing. © 2007 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Krack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P. D., Benazzouz, A., LeBas, J. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035275 · Cited by 2,249
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa000827 · Cited by 1,514
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes
Kleiner-Fisman, G., Herzog, J., Fisman, D. N., Tamma, F., Lyons, K. E., Pahwa, R., Lang, A. E., & Deuschl, G. (2006) · Movement Disorders · doi:10.1002/mds.20962 · Cited by 957
Cited by
Parkinson’s Disease in Women and Men: What’s the Difference?
Cerri, S., Mus, L., & Blandini, F. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191683 · Cited by 800
Molecular mechanisms of L-DOPA-induced dyskinesia
Jenner, P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2471 · Cited by 523
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
Self-citationNMDA receptors in clinical neurology: excitatory times ahead
Kalia, L. V., Kalia, S. K., & Salter, M. W. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70165-0 · Cited by 415
Voon, V., Fernagut, P.-O., Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., Juncos, J. L., Obeso, J. A., & Bezard, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70287-x · Cited by 335
Paul, M., Graybiel, A., David, J., & Robertson, H. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-10-03729.1992 · Cited by 299
Thanvi, B., Lo, N., & Robinson, T. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.054759 · Cited by 281
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Self-citationNicotine and Parkinson's disease: implications for therapy
Quik, M., O'Leary, K., & Tanner, C. M. (2008) · Movement Disorders · doi:10.1002/mds.21900 · Cited by 154
Huot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153
Self-citationBordia, T., Campos, C., Huang, L., & Quik, M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140897 · Cited by 120
“…in the basal ganglia have been reported to exert beneficial effects against dyskinetic-like movements in parkinsonian animal models, including the glutamate, adenosine, noradrenaline, 5-hydroxytryptamine, cannabinoid, and opioid systems (Brotchie, 2005; Fox et al., 2006; Fabbrini et al., 2007).”
Higher iron in the red nucleus marks Parkinson's dyskinesia
Lewis, M. M., Du, G., Kidacki, M., Patel, N., Shaffer, M. L., Mailman, R. B., & Huang, X. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.025 · Cited by 84
Crittenden, J. R., Zhai, S., Sauvage, M., Kitsukawa, T., Burguière, E., Thomsen, M., Zhang, H., Costa, C., Martella, G., Ghiglieri, V., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105473 · Cited by 19
Metadata
- Authors
- Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., & Goetz, C. G.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2007-04-11
- Volume
- 22
- Issue
- 10
- Pages
- 1379-1389
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2121928725
- Cited by
- 464
- References
- 72
- FWCI
- 17.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.